All News

DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Belimumab in Lupus Nephritis

Jack Cush, MD

Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.

Read Article
RheumNow Podcast square

3-4-5 Rule (5.26.2023)

Jack Cush, MD

Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.

Read Article
lupus_0.jpg

Lupus Landmark Study to Accelerate Personalized Lupus Treatments

EurekAlert!

The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics today announced the launch of the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus.

Read Article
RheumNow Podcast square

Allergic Drug-Induced Arthritis (5.19.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

Read Article
PSS.scleroderma.arthritis.contractures

Juvenile and Adult-onset Scleroderma Differ

Jack Cush, MD

A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.  

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

ICYMI: Our old friend, hydroxychloroquine

Eric Dein, MD

After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.

Read Article
Sjogren_syndrome_salivary%20bx%282%29.jpg

B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's

MedPage Today

Genetic blood tests indicated that Bruton's tyrosine kinase (BTK) and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported, suggesting that BTK inhibitors might be useful in this population.

Read Article
arthritis,gout,autoimmune,Dx,lab

One in Ten has Autoimmune Disease

Jack Cush, MD

A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals.

Read Article
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
SLE & dsDNA: 3,484 SLE pts (over 37,582 visits) - 29.5% had persistently dsDNA+ & 34% had fluctuating dsDNA.results & both assoc w/ SLE flares (HR 1.56 & 1.46). Doubling of dsDNA assoc w/ 33-36% increased risk of flare (p=0.009) https://t.co/quVlHrfSl3 https://t.co/DkD3h1wV6w

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Our old friend, hydroxychloroquine https://t.co/NouJayD0T3 https://t.co/lRBl0UQuY3

Links:

Dr. John Cush RheumNow ( View Tweet)
Lit review of 2236 articles found only 28 w/ Post-COVID autoimmune Dx (64% F; age 51 yrs) - that included 11 (39) IIM (w/ 4 DM); 7 (25%) SLE; 4 (14%) anti-synthetase syndrome; 4 (14%) SSc; 1 lupus/MCTD overlap. Mean onset 23.7 d post COVID https://t.co/jtRaqIBGH1 https://t.co/WilcRFNAL9

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of the etiology of Polyserositis (14 pts, 23 articles): most common - neoplasia (26.3%; Lung Lymphoma; ovarian; pancreatic), autoimmune (16.7% - SLE, AOSD) & infections (12.3%; coxackie, CMV, mTB). https://t.co/Bubd99ETgu https://t.co/VbiPB0y7pv

Links:

Dr. John Cush RheumNow ( View Tweet)
Chinese study of 4091 SLE pts, 3% (106) dx w/ osteonecrosis (AVN). AVN risk factors included: - SLE onset age ≤ 30 (HR 1.6) - Arthritis (HR 1.6) - Organ damage (HR 2.6) - RNP+ (HR 1.7) - High steroid doses (HR 1.7) https://t.co/DnqhEIWztY https://t.co/aP0uh0oh1x

Links:

Dr. John Cush RheumNow ( View Tweet)
Comprehensive full read review of Cutaneous Lupus Erythematosus - pathogenesis, pathology and treatment options. https://t.co/J7C0511kBJ https://t.co/ILhcpeT5cx

Links:

Dr. John Cush RheumNow ( View Tweet)
One in Ten has Autoimmune Disease A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals. https://t.co/a2VbAO0Fc6 https://t.co/69Yl9OTtKY

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/0mC7PxF0DU https://t.co/klbnwjcPbM

Links:

Dr. John Cush RheumNow ( View Tweet)
Treatment and Management of Neuropsychiatric Lupus On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. https://t.co/99GXxyIjLl https://t.co/Bor7R2qVtN

Links:

Dr. John Cush RheumNow ( View Tweet)
Full Read comprehensive revie by Isenberg on what Rx work in SLE; they review RCT data on approved drugs and Rx in development: - Obinutuzumab - Dapirolizumab - Deucravacitinib - Litifilimab - Atacicept - Telitacicept https://t.co/WZQ3soseDB https://t.co/UdkmFYhbGv

Links:

Dr. John Cush RheumNow ( View Tweet)
Lupus During Pregnancy Carries Higher Maternal, Fetal Morbidity Risks Women with SLE had higher risks for maternal and fetal morbidity compared to those without the chronic autoimmune disorder, according to a nationwide analysis of U.S. data. https://t.co/iD4pGZPzQm https://t.co/zl9lX7i8es

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×